News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

INSYS Therapeutics To Report Fourth Quarter And Year-End 2013 Financial Results On March 4


2/13/2014 9:55:47 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PHOENIX, AZ--(Marketwired - February 12, 2014) - Insys Therapeutics, Inc. (NASDAQ: INSY), a specialty pharmaceutical company that develops and commercializes innovative supportive care products, today announced that the Company will release its fourth quarter and year-end 2013 financial results on Tuesday, March 4, 2014, before the market opens.

Following the release of the financial results, Michael L. Babich, President and Chief Executive Officer, and Darryl S. Baker, Chief Financial Officer, will host a conference call at 11:00 a.m. Eastern Standard Time.

Interested parties may participate in the conference call by dialing 888-427-9376 (U.S.) or 719-325-2308 (International), 5-10 minutes prior to the start of the call. A replay will be available shortly after the completion of the call for two weeks by dialing 888-203-1112 (U.S.) or 719-457-0820 (International) and entering conference call ID number 8377866. A live audio webcast and archive of the call will also be available at www.insysrx.com.

About Insys Therapeutics, Inc.
Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care products, with a focus on utilizing its proprietary formulation technologies to address the clinical shortcomings of existing commercial pharmaceutical products. The company has two marketed products including Subsys, a proprietary sublingual fentanyl spray for breakthrough pain in opioid-tolerant cancer patients. Insys markets Subsys through its incentive-based, cost-efficient commercial sales force. The company's lead product candidate is Dronabinol Oral Solution, a proprietary orally administered liquid formulation of dronabinol, which would be its second branded supportive care product, if approved.


Contacts:
Darryl S. Baker
Chief Financial Officer
Insys Therapeutics, Inc.
602-910-2617

Lisa M. Wilson
President
In-Site Communications, Inc.
212-452-2793
E: lwilson@insitecony.com



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES